Cyrcadia, Inc. Collaborates With the Canary Foundation for Early Breast Cancer Research

Reno, Nev. (PRWEB)September 22, 2015 via http://www.prweb.com/releases/2015/09/prweb12974574.htm Cyrcadia Health and the Canary Foundation announced their intention to enter into collaborative research on improved early cancer detection screening through the use of Cyrcadia’s wearable devices. Through funding support from the Canary Foundation, Cyrcadia has established a multi-site trial, beginning at a leading Bay Area cancer hospital with near term expansion to the Stefanie Spielman Comprehensive Breast Foundation at The Ohio State University. This research will involve a 173 patient study focused on early breast cancer health screening. “We are excited that the Canary Foundation has taken an interest in our personalized health screening technology,” said Rob Royea, president of Cyrcadia, Inc.    “The potential of collaboration with the only foundation in the world, which over the past 10 years has focused solely on early cancer detection, is highly prestigious. Working together on early biomarker identification for multiple states of cancer will be of significant benefit to our research. Our ability to correlate our findings with those biomarkers which are early indicators of breast cancer infusion is invaluable and could lead to additional applications for our wearable products.” One in eight women in the U.S. alone are diagnosed with breast cancer annually. Approximately 500,000 die worldwide from the disease each year, many due to lack of early detection. The company’s wearable, smartphone enabled technology, called the iTBraTM, uses a comfortable data collection device placed under a bra to collect from two to 12 hours of breast cell data (dynamic cell chaos). Circadian rhythm-based temperature variances of cell cycles are then measured through a patented process to identify abnormalities at the earliest stages of...

Cyrcadia, Inc. Announces ClinicalTrials.gov Listing for Its Entry into Clinical Trials for Wearable Breast Cancer Detection Device

Reno, Nev. Aug. 11, 2015 — Cyrcadia, Inc. (“Company”) announces its clinical trial listing on ClinicalTrials.gov for its wearable breast cancer early detection device at El Camino Hospital, in Mountain View, California and upcoming additional clinical study sites. ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, currently holding registrations from over 130,000 trials from more than 170 countries in the world. “We are enthused that we have initiated the El Camino Hospital trial in Mt. View, CA and have now finalized the ClinicalTrials.gov registry. We look forward to the additions of The James Cancer Hospital at The Ohio State University and the Canary Center at Stanford’s upcoming inclusion into our early breast cancer screening trials,” says Rob Royea, President of Cyrcadia, Inc. For those interested in learning more about the Cyrcadia clinical studies, ClinicalTrials.gov is the registry to use including all details about the study and its status. It is the only location where Cyrcadia will divulge information about the studies and will update the registry from time to time. All information desired about the clinical studies can be obtained there and will not otherwise be divulged by Cyrcadia, its staff or other related parties. All details about the study including descriptions, eligibility and contacts can be obtained there. Please follow this link: ClinicalTrials.gov/Cyrcadia or go to the clinicaltrials.gov website using the identifier NCT02511301 to learn more and follow progress of the study as it is reported. Utilizing its previous FDA cleared device as a...

Cyrcadia, Inc. Enters Clinical Trials for Wearable Breast Cancer Detection Device

Reno, Nev. (PRWEB)July 07, 2015 Cyrcadia, Inc. (“Company”) announces it is entering into a clinical trial for its wearable breast cancer early detection device and is enrolling the first clinical trial participants at El Camino Hospital, in Mountain View, California. Utilizing its previous FDA cleared device as a predicate, Cyrcadia Health™ (a division of Cyrcadia, Inc.) is combining the Company’s fourth generation, wearable device technology, made by Flextronics, and the SalesForce database software, to track the clinical results. “We are targeting both the 70% of the population that undergo biopsies on non-cancerous tissue resulting from mammographic referral, as well as mass screening of patients with dense breasts,” said Rob Royea, president of Cyrcadia Health. “Patients with dense breast tissue have a higher propensity for cancer. Furthermore, mammography is challenged by detecting cancer in dense breast tissue as it can mask cancer cells and lesions.” Following successful completion of the clinical trials, the Company intends to produce a wearable, smart phone enabled technology, called the iTBraTM, which will utilize a comfortable data collection device placed under a bra to collect from two to twelve hours of breast cell data (dynamic cell chaos). Circadian rhythm-based temperature variances of cell cycles are then measured through a patented process to identify abnormalities at the earliest stages of cellular change, the results of which are transferred through a smart device to a global cancer library, where advanced analytical analysis occurs, and results are communicated back to the patient and physician. “El Camino Hospital is pleased to be involved in Cyrcadia Health’s research study to evaluate this potential new technology,” said Katherine Sutherland, MD, co-investigator...

ABC 7 NEWS: A new technology that could revolutionize breast cancer screening is about to begin clinical trials in the Bay Area.

ABC 7 NEWS: High-tech bra helps detect breast cancer High-tech bra helps detect breast cancer. Friday, January 30, 2015 12:11AM MOUNTAIN VIEW, Calif. (KGO) — A new technology that could revolutionize breast cancer screening is about to begin clinical trials in the Bay Area. Rather than a mammogram or ultrasound, this system can be used at home, with potentially life-saving information transmitted through a smartphone. For Dian Gaxiola, a routine breast screening at El Camino Hospital in Mountain View turned out to be a lifesaver. Doctors caught her cancer at a very early stage and saved her breast. “I was very lucky, I think because of the early detection,” cancer survivor Dian Gaxiola said. El Camino Hospital Radiologist Dr. Sila Yitta says routine mammograms and self-screening are the best defense, although many women don’t always take advantage. “In my experience it is hit or miss, I think women, some women are consistent in doing breast exams at home, some women don’t do them at all, and I often times get questions from women, asking simply, ‘How do I do an exam,'” Yitta said. However soon, an experimental technology could help thousands of women and doctors screen for breast cancer in a new way. It’s called the iTBra. “So you’ll be putting that on, so it’ll now be centered over you,” Cyrcadia Health CEO Rob Royea says the patches can be worn inside any normal bra. He said, “It’s a wearable device with a number of sensors that check what happens with your circadian patterns of heat change on your breast over time.” Roye says the heat changes correlate to...

Early Detection – Nedra

The opportunity of early detection and management of breast tissue abnormalities is a reality and has already made significant impacts in many lives. Nedra’s story is just one of those. Please take a moment to hear about the impact of the Cyrcadia Health technology in Nedra’s life, along with support and thoughts of the primary investigator of this particular study, Dr. Ronald...

First Warning Systems Changes Name to Cyrcadia Health

FIRST WARNING SYSTEMS CHANGES NAME TO CYRCADIA HEALTH TO BETTER REFLECT CORE COMPETENCY AND GOALS OF COMPANY Pioneer in Early Cancer Detection Receives $1 Million in Angel Funding Enabling the Final Stages of Clinical Validation Reno, Nev. – Sept. 30, 2014 – First Warning Systems, a pioneer in early cancer detection through measuring abnormal circadian cellular changes throughout the body, announced the company is changing its name to Cyrcadia Health, Inc. to better address the company’s breadth of upcoming product releases. The initial focus will be on wearable early breast cancer screening technology. “Our initial focus will be an ‘Internet of Everthing,’ wearable early breast cancer system which detects abnormal circadian cellular changes over time,” said Rob Royea, president and CEO of Cyrcadia Health. “With our most recent infusion of capital, we are able to take this unique technology into final clinical validation trials in the U.S. starting in November. It is our intention to launch this product into South Asia and Europe in mid-2015 followed by the U.S. after final FDA clinical clearance.” The company’s wearable, smart phone enabled technology, called the iTBraTM, uses a comfortable data collection device placed under a bra to collect 2-12 hours of breast cell data (dynamic cell chaos). Circadian rhythm-based temperature variances of cell cycles are then measured through a patented process to identify abnormalities at the earliest stages of cellular change, the results of which are transferred through a smart device to a global cancer library and communicated back to the patient and physician. “We have historically raised $1.9 Million in seed monies for the launch of our upcoming technologies” said...